Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Pfizer stock (PFE)

Buy Pfizer stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Pfizer (PFE) is a leading drug manufacturers - general business based in the US. It opened the day at $25.74 after a previous close of $25.23. During the day the price has varied from a low of $25.59 to a high of $26.10. The latest price was $25.73 (25 minute delay). Pfizer is listed on the NYSE and employs 88,000 staff. All prices are listed in US Dollars.

Our top picks for where to buy Pfizer stock

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Earn up to $300 with qualifying deposits
  • Discover new opportunities with Opto's AI-driven thematic investing system
  • Theme and ETF screener

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options with no options contract fees
  • Complimentary access to a financial planner

Top pick for best mobile experience

Go to site
  • Trade $0 commission stocks, ETFs, and options with as little as $1
  • After-hours trading available
  • Earn 4.5% interest on uninvested cash with Gold
  • 24/7 customer support

How to buy Pfizer stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – PFE. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Pfizer stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 6 of 6
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
OPTO
Finder Score: 3.8 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
SoFi Invest®
Finder Score: 4.3 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a complimentary access to financial planners.
Robinhood
Finder Score: 4.6 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
Uphold
Finder Score: 3.6 / 5: ★★★★★
Crypto alternative
Uphold
★★★★★
Cryptocurrency
N/A
$0
4.65%
Get $10
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
Public.com
Finder Score: 4.4 / 5: ★★★★★
Public.com
★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
$0
$0
4.35%
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Pfizer stock price (NYSE: PFE)

Use our graph to track the performance of PFE stocks over time.

Pfizer shares at a glance

Information last updated 2024-12-09.
Open$0.00
High$0.00
Low$0.00
Close$0.00
Previous close$0.00
Change $0.00
Change % N/A%
Volume 0
Information last updated 2024-12-05.
52-week range$24.11 - $31.06
50-day moving average $27.75
200-day moving average $28.05
Wall St. target price$32.60
PE ratio 34.0946
Dividend yield $1.67 (6.57%)
Earnings per share (TTM) $0.74

Is it a good time to buy Pfizer stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pfizer price performance over time

Historical closes compared with the close of $25.73 from 2024-12-04

1 week (2024-12-02) -0.35%
1 month (2024-11-08) -3.71%
3 months (2024-09-09) -12.51%
6 months (2024-06-07) -9.97%
1 year (2023-12-08) -10.60%
2 years (2022-12-09) -44.82%
3 years (2021-12-09) 45.4729
5 years (2019-12-09) 29.3029

Is Pfizer stock undervalued or overvalued?

Valuing Pfizer stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pfizer's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Pfizer's P/E ratio

Pfizer's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, Pfizer shares trade at around 34x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Pfizer's PEG ratio

Pfizer's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.1802. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Pfizer's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Pfizer's EBITDA

Pfizer's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $18.4 billion.

The EBITDA is a measure of a Pfizer's overall financial performance and is widely used to measure a its profitability.

Pfizer financials

Revenue TTM $59.4 billion
Operating margin TTM 32.99%
Gross profit TTM $66.2 billion
Return on assets TTM 3.31%
Return on equity TTM 4.54%
Profit margin 7.16%
Book value $16.29
Market Capitalization $143 billion

TTM: trailing 12 months

Pfizer's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Pfizer.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Pfizer's total ESG risk score

Total ESG risk: 33.15

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Pfizer's overall score of 33.15 (as at 12/31/2018) is pretty weak – landing it in it in the 60th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Pfizer is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Pfizer's environmental score

Environmental score: 7/100

Pfizer's environmental score of 7 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Pfizer is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Pfizer's social score

Social score: 18.47/100

Pfizer's social score of 18.47 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that Pfizer is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Pfizer's governance score

Governance score: 13.68/100

Pfizer's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that Pfizer is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Pfizer's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Pfizer scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Pfizer hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Pfizer Inc was last rated for ESG on: 2019-01-01.

Total ESG score 33.15
Total ESG percentile 60
Environmental score 7
Environmental score percentile 6
Social score 18.47
Social score percentile 6
Governance score 13.68
Governance score percentile 6
Level of controversy 3

Pfizer share dividends

65%

Dividend payout ratio: 65.12% of net profits

Recently Pfizer has paid out, on average, around 100% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Pfizer shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Pfizer's case, that would currently equate to about $1.67 per share.

Pfizer's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Pfizer's most recent dividend payout was on 1 December 2024. The latest dividend was paid out to all shareholders who bought their shares by 7 November 2024 (the "ex-dividend date").

Have Pfizer's shares ever split?

Pfizer's shares were split on a 1054:1000 basis on 16 November 2020 . So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1054 shares. This wouldn't directly have changed the overall worth of your Pfizer shares – just the quantity. However, indirectly, the new 5.1% lower share price could have impacted the market appetite for Pfizer shares which in turn could have impacted Pfizer's share price.

Pfizer share price volatility

Over the last 12 months, Pfizer's shares have ranged in value from as little as $24.1057 up to $31.0576. A popular way to gauge a stock's volatility is its "beta".

PFE.US volatility(beta: 0.62)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Pfizer's is 0.615. This would suggest that Pfizer's shares are less volatile than average (for this exchange).

Pfizer overview

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.

Frequently asked questions

null
What percentage of Pfizer is owned by insiders or institutions?
Currently 0.048% of Pfizer shares are held by insiders and 67.814% by institutions.
How many people work for Pfizer?
Latest data suggests 88,000 work at Pfizer.
When does the fiscal year end for Pfizer?
Pfizer's fiscal year ends in December.
Where is Pfizer based?
Pfizer's address is: 66 Hudson Boulevard East, New York, NY, United States, 10001-2192
What is Pfizer's ISIN number?
Pfizer's international securities identification number is: US7170811035
What is Pfizer's CUSIP number?
Pfizer's Committee on Uniform Securities Identification Procedures number is: 717081103

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site